Sponsored Links
| Millennium And Seattle Genetics Present Clinical Data On ADCETRIS™ (Brentuximab Vedotin) In Hodgkin Lymphoma At EHA Annual Meeting |
 |
 |
 |
| Medical News - Hematology | |||
|
Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (Nasdaq: SGEN), announced today that data on ADCETRIS™ (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma patients were featured in an oral presentation at the 16th Congress of the European Hematology Association (EHA) in London... Read more: Blood / Hematology News From Medical News Today
|